News
Effect of Azacitidine in the Treatment of Acute Myeloid Leukemia on Long-Term Patient Survival
The work cited below presents freshly updated results from the Quazar AML-001 study evaluating azacitidine (AZA) in the treatment of acute myeloid leukemia (AML), now with a median follow-up period of 55.5 months. Among other things, clinical and biological variables predictive of long-term survival, defined here as survival ≥ 3 years from randomization within the study, were examined.
Oral Azacitidine Prolongs Survival of AML Patients Regardless of Measurable Residual Disease
Intensive chemotherapy for patients newly diagnosed with acute myeloid leukemia (AML) often…
Vaccination and ALEmtuzumab: ALE when?
When, why and against what should patients with multiple sclerosis treated with alemtuzumab be…
Traveling with MS – Is Vaccination a Limitation?
What about the need for vaccination when traveling abroad? Which vaccines should you be cautious…
Can Ketogenic Diet or Intermittent Fasting Help Patients with DM2 in Controlling Weight and Glycemia?
The foundation of managing type 2 diabetes mellitus (DM2) typically involves lifestyle adjustments,…
New Type of Fixation Allows Regular Limb Hygiene and Stay in Water
Conservative therapy for injuries and non-traumatic diseases of the musculoskeletal system is a…
Predictors and Rate of Anticoagulant Therapy Discontinuation in Patients with Atrial Fibrillation
With the worldwide increase in the prevalence of atrial fibrillation (AF), the use of…
Association Between Sartan Therapy and Lower Incidence of Epilepsy in Hypertensive Patients?
Arterial hypertension (AH) is one of the non-cerebral comorbidities of epilepsy, with the…
RETRO-TAS Study – Trifluridine/Tipiracil in Pretreated mCRC in Real-World Practice
How does trifluridine/tipiracil (FTD/TPI), which demonstrated efficacy in clinical trials in…
Study TACTIC – Efficacy and Safety of Trifluridine/Tipiracil in Pre-treated mCRC Patients in Real-world Practice
In the pivotal phase III RECOURSE randomized placebo-controlled study, therapy with…